Apellis Pharmaceuticals (1APLS) Stock Overview
A commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
1APLS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Apellis Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.37 |
| 52 Week High | US$24.26 |
| 52 Week Low | US$17.23 |
| Beta | 0.36 |
| 1 Month Change | 0.79% |
| 3 Month Change | -1.45% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 32.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1APLS | IT Biotechs | IT Market | |
|---|---|---|---|
| 7D | -3.8% | -0.7% | 1.7% |
| 1Y | n/a | 18.1% | 28.0% |
Return vs Industry: Insufficient data to determine how 1APLS performed against the Italian Biotechs industry.
Return vs Market: Insufficient data to determine how 1APLS performed against the Italian Market.
Price Volatility
| 1APLS volatility | |
|---|---|
| 1APLS Average Weekly Movement | 11.6% |
| Biotechs Industry Average Movement | 7.3% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in IT Market | 6.8% |
| 10% least volatile stocks in IT Market | 2.4% |
Stable Share Price: 1APLS's share price has been volatile over the past 3 months compared to the Italian market.
Volatility Over Time: 1APLS's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Italian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 708 | Cedric Francois | apellis.com |
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA.
Apellis Pharmaceuticals, Inc. Fundamentals Summary
| 1APLS fundamental statistics | |
|---|---|
| Market cap | €2.79b |
| Earnings (TTM) | €38.41m |
| Revenue (TTM) | €867.80m |
Is 1APLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1APLS income statement (TTM) | |
|---|---|
| Revenue | US$1.02b |
| Cost of Revenue | US$411.35m |
| Gross Profit | US$605.05m |
| Other Expenses | US$560.06m |
| Earnings | US$44.99m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.36 |
| Gross Margin | 59.53% |
| Net Profit Margin | 4.43% |
| Debt/Equity Ratio | 113.3% |
How did 1APLS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/05 22:14 |
| End of Day Share Price | 2026/01/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Apellis Pharmaceuticals, Inc. is covered by 34 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ulz | Baird |
| Colleen Kusy | Baird |
| Matthew Luchini | BMO Capital Markets Equity Research |